159992 创新药
已收盘 03-28 15:00:00
资讯
新帖
简况
《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元 创新药收入占比提升
阿斯达克财经 · 03-28 10:08
《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元 创新药收入占比提升
【券商聚焦】招银国际微削信达生物(01801)目标价4% 仍为该行在创新药板块首选标的
金吾财讯 · 03-22
【券商聚焦】招银国际微削信达生物(01801)目标价4% 仍为该行在创新药板块首选标的
短剧游戏板块拉升 创新药板块走势分化|板块牛熊榜
第一财经 · 03-20
短剧游戏板块拉升 创新药板块走势分化|板块牛熊榜
东诚药业旗下米度生物融资近4亿聚焦创新药
证券时报 · 03-19
东诚药业旗下米度生物融资近4亿聚焦创新药
商业健康险去年对创新药支付总额达74亿元
港股那点事 · 03-18
商业健康险去年对创新药支付总额达74亿元
美国BIO称将剔除药明康德会员资格 创新药板块迎来冲击?
券商中国 · 03-14
美国BIO称将剔除药明康德会员资格 创新药板块迎来冲击?
创新药板块集体拉升 多股涨超10% 机构:行业有望进入良性提质增速阶段
第一财经 · 03-14
创新药板块集体拉升 多股涨超10% 机构:行业有望进入良性提质增速阶段
网传文件被传重磅利好!港股创新药概念股集体走高
老虎资讯综合 · 03-14
网传文件被传重磅利好!港股创新药概念股集体走高
创新药行业迎来全链条政策支持,产业链正逐渐崛起
格隆汇 · 03-14
创新药行业迎来全链条政策支持,产业链正逐渐崛起
中国生物制药两款创新药将在AACR公布共5项研究结果
阿斯达克财经 · 03-12
中国生物制药两款创新药将在AACR公布共5项研究结果
两会共话|如何促进国产创新药高质量发展?多位代表委员支招
澎湃新闻 · 03-10
两会共话|如何促进国产创新药高质量发展?多位代表委员支招
3月7日华夏嘉实大成国投瑞银等基金大咖说:热辣滚烫的投资“基”会——可转债!聊聊创新药行业的几条主线
新浪基金 · 03-06
3月7日华夏嘉实大成国投瑞银等基金大咖说:热辣滚烫的投资“基”会——可转债!聊聊创新药行业的几条主线
众生药业公告,控股子公司一类创新药RAY
港股那点事 · 02-27
众生药业公告,控股子公司一类创新药RAY
众生药业:控股子公司一类创新药RAY12
港股那点事 · 02-21
众生药业:控股子公司一类创新药RAY12
创新药物马立巴韦片在中国投入临床使用
美通社 · 02-09
创新药物马立巴韦片在中国投入临床使用
东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权
阿斯达克财经 · 02-09
东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权
远大医药(00512.HK)创新药Ryaltris向药监局递交NDA获得受理
阿斯达克财经 · 02-08
远大医药(00512.HK)创新药Ryaltris向药监局递交NDA获得受理
康哲药业(00867.HK)两款创新药获临床试验批准
阿斯达克财经 · 02-08
康哲药业(00867.HK)两款创新药获临床试验批准
加载更多
公司概况
公司名称:
--
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.7,"timestamp":1711609413000,"preClose":0.693,"halted":0,"volume":283283119,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","marketStatusCode":5,"change":0.007,"latestTime":"03-28 15:00:00","open":0.692,"high":0.708,"low":0.689,"amount":198000000,"amplitude":0.0274,"askPrice":0.7,"askSize":16067,"bidPrice":0.699,"bidSize":9166,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1711675800000},"adr":0,"adjPreClose":0.693,"symbolType":"fund","openAndCloseTimeList":[[1711589400000,1711596600000],[1711602000000,1711609200000]],"highLimit":0.762,"lowLimit":0.624,"ibTradeSell":false,"ibTradeBuySell":true,"pbRate":0,"committee":0.265412,"marketValue":0,"floatMarketCap":0,"changeRate":0.0101,"turnoverRate":0,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-04-02。","discountRate":"0.00%","netWorth":"0.000"},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2422901984","title":"《大行报告》中金升翰森制药(03692.HK)目标价27.2%至17.81元 创新药收入占比提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2422901984","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422901984?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:08","pubTimestamp":1711591680,"startTime":"0","endTime":"0","summary":"中金发表报告指,翰森制药去年收入101亿元人民币,按年增长7.7%;净利润32.8亿元人民币,按年增长26.9%,高于该行预期,主因产品对外授权的首付款记账。该行指,关注翰森制药今年创新药进一步放量和早期临床管线数据读出。中金指,由于合作首付款记账部分将于今年确认,加上预期公司三费控制良好,因此上调今年收入和净利润预测各2%和11%至115.66和34.3亿人民币,首次引入明年盈利预测35.6亿元。维持“跑赢行业”评级,上调目标价27.2%至17.81港元。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201021164017612_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338136/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2421085590","title":"【券商聚焦】招银国际微削信达生物(01801)目标价4% 仍为该行在创新药板块首选标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2421085590","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2421085590?lang=zh_cn&edition=full","pubTime":"2024-03-22 14:10","pubTimestamp":1711087819,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研报指,信达生物 2023年录得总收入62.1亿元人民币,其中产品销售收入57.3亿元人民币,符合该行的预期。信达生物2H23表现强劲,产品销售额较上半年增长33.1%。信达生物还在探索IBI343与自有PD-1信迪利单抗和VEGFR-2雷莫芦单抗联合用于1L和2LGC的潜力。该行认为IBI343由于优秀的安全性和令人满意的疗效而具有全球BIC潜力。该行指,信达生物是该行在创新药板块的首选标的,该行调整公司目标价为55.00港元,维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1933865","is_publish_highlight":false,"gpt_icon":0},{"id":"2420760173","title":"短剧游戏板块拉升 创新药板块走势分化|板块牛熊榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2420760173","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2420760173?lang=zh_cn&edition=full","pubTime":"2024-03-20 12:32","pubTimestamp":1710909120,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 早盘短剧游戏板块震荡拉升,华策影视20CM涨停,慈文传媒、掌阅科技、中广天择涨停,唐德影视、捷成股份等跟涨。创新药板块走势分化,亚太药业、常山药业、长春高新等跌幅居前。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-20/doc-inanxxcv6182921.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-20/doc-inanxxcv6182921.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420237265","title":"东诚药业旗下米度生物融资近4亿聚焦创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2420237265","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2420237265?lang=zh_cn&edition=full","pubTime":"2024-03-19 07:03","pubTimestamp":1710802980,"startTime":"0","endTime":"0","summary":" 3月18日,东诚药业公告,同意下属子公司米度(烟台)生物技术有限公司增资扩股,由国投招商领投,国投聚力、山东地方产业基金等跟投,合计融资近4亿元。 在非核药领域,米度生物作为分子影像CRO,在小分子、多肽、抗体、多糖、细胞治疗等创新品类上的临床前分子标记能力卓越,具有良好的放射性示踪剂生产和影像分析能力,并获得全球知名药企的认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-03-19/doc-inanvcia9687900.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-03-19/doc-inanvcia9687900.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2420465045","title":"商业健康险去年对创新药支付总额达74亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420465045","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2420465045?lang=zh_cn&edition=full","pubTime":"2024-03-18 06:16","pubTimestamp":1710713760,"startTime":"0","endTime":"0","summary":"自2015年药品审评审批制度改革以来,我国创新药产业新药获批数量逐年增加,上市速度大大加快。日前,由波士顿咨询、中再寿险以及镁信健康共同编撰的《中国商业健康险创新药支付白皮书(2024)》(简称《白皮书》)正式发布。《白皮书》调查研究显示,2023年创新药市场规模约1400亿元,商业健康险对创新药的支付总额约74亿元,占整体市场规模的5.3%。 \n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-18/doc-inanstzy5857435.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-18/doc-inanstzy5857435.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419611441","title":"美国BIO称将剔除药明康德会员资格 创新药板块迎来冲击?","url":"https://stock-news.laohu8.com/highlight/detail?id=2419611441","media":"券商中国","top":-1,"share":"https://www.laohu8.com/m/news/2419611441?lang=zh_cn&edition=full","pubTime":"2024-03-14 11:08","pubTimestamp":1710385680,"startTime":"0","endTime":"0","summary":" 创新药的崛起之路似乎并不平坦! 昨晚传出的一份《关于全链条支持创新药发展实施方案的征求意见稿》刺激了市场的神经。今天早盘,港股创新药ETF一度飙涨近10%。原因还是药明康德,这只股票亦是高开低走,大跌近5%。3月13日晚间,就在国内在为创新药利好欢呼之时,据美国知名生物技术组织BIO官网公布,宣布将剔除WuXi会员资格,并将终止与其合作。对于整个创新药板块是否也有冲击?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/jsy/2024-03-14/doc-inanhefw7961183.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/jsy/2024-03-14/doc-inanhefw7961183.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419194076","title":"创新药板块集体拉升 多股涨超10% 机构:行业有望进入良性提质增速阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2419194076","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2419194076?lang=zh_cn&edition=full","pubTime":"2024-03-14 10:02","pubTimestamp":1710381720,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 截至发稿,诺思格、泰格医药、昭衍新药、奥赛康、赛隆药业等多股涨停。 3月14日早盘,创新药板块大幅高开。 国开证券表示,今年以来,关于创新药顶层支持政策不断,同时创新药成功“出海”频出,行业有望进入良性提质增速阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-03-14/doc-inanfxxy8066621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-03-14/doc-inanfxxy8066621.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"1182047658","title":"网传文件被传重磅利好!港股创新药概念股集体走高","url":"https://stock-news.laohu8.com/highlight/detail?id=1182047658","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1182047658?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:37","pubTimestamp":1710380248,"startTime":"0","endTime":"0","summary":"3月14日,港股创新药概念股集体走高,$泰格医药(03347)$涨超22%,$荣昌生物(09995)$涨超10%,消息面上,网传一份《全链条支持创新药发展实施方案(征求意见稿)》的文件,被市场解读为创新药行业的重磅利好。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2419694951","title":"创新药行业迎来全链条政策支持,产业链正逐渐崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2419694951","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2419694951?lang=zh_cn&edition=full","pubTime":"2024-03-14 09:34","pubTimestamp":1710380049,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418933633","title":"中国生物制药两款创新药将在AACR公布共5项研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2418933633","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2418933633?lang=zh_cn&edition=full","pubTime":"2024-03-12 00:52","pubTimestamp":1710175920,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布,附属正大天晴开发的两款创新药“盐酸安罗替尼胶囊”、“TQB2916(CD40激动剂)”将在2024年美国癌症协会年会“AACR”公布5项研究成果。安罗替尼是一款口服新型小分子多靶点受体酪氨酸激酶抑制剂(TKI),能有效抑制VEGFR 1-3等激酶,通过调控肿瘤微环境重编程达到抑制肿瘤血管新生、抑制肿瘤生长、调控免疫微环境的作用。CD40激动剂主要通过激活抗原提呈细胞(APC)促进免疫细胞的活化发挥肿瘤抑制作用。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-11 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1332490/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2418483132","title":"两会共话|如何促进国产创新药高质量发展?多位代表委员支招","url":"https://stock-news.laohu8.com/highlight/detail?id=2418483132","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2418483132?lang=zh_cn&edition=full","pubTime":"2024-03-10 06:54","pubTimestamp":1710024840,"startTime":"0","endTime":"0","summary":" 今年政府工作报告在介绍2024年政府工作任务“大力推进现代化产业体系建设,加快发展新质生产力”时提出,加快前沿新兴氢能、新材料、创新药等产业发展,积极打造生物制造、商业航天、低空经济等新增长引擎。 澎湃新闻注意到,今年全国两会上,围绕如何推动国产创新药高质量发展,多位人大代表、委员积极建言献策。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-10/doc-inamutfu0306587.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-10/doc-inamutfu0306587.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417651232","title":"3月7日华夏嘉实大成国投瑞银等基金大咖说:热辣滚烫的投资“基”会——可转债!聊聊创新药行业的几条主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2417651232","media":"新浪基金","top":-1,"share":"https://www.laohu8.com/m/news/2417651232?lang=zh_cn&edition=full","pubTime":"2024-03-06 15:26","pubTimestamp":1709709960,"startTime":"0","endTime":"0","summary":" 2024-03-07 16:00合信岛春季集训营丨如何走进美丽人生下半场?从摸爬滚打到内心丰盈。 2024-03-07 19:30嘉实基金谭丽、晓鸥姐姐:播种2024,静待花开。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/2024-03-06/doc-inamkitk8808808.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2024-03-06/doc-inamkitk8808808.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2414824186","title":"众生药业公告,控股子公司一类创新药RAY","url":"https://stock-news.laohu8.com/highlight/detail?id=2414824186","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2414824186?lang=zh_cn&edition=full","pubTime":"2024-02-27 18:05","pubTimestamp":1709028300,"startTime":"0","endTime":"0","summary":"众生药业公告,控股子公司一类创新药RAY1225注射液用于2型糖尿病患者的II期临床试验完成首例受试者入组。 \n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-27/doc-inaknpfi3369332.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-27/doc-inaknpfi3369332.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413449432","title":"众生药业:控股子公司一类创新药RAY12","url":"https://stock-news.laohu8.com/highlight/detail?id=2413449432","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2413449432?lang=zh_cn&edition=full","pubTime":"2024-02-21 19:09","pubTimestamp":1708513740,"startTime":"0","endTime":"0","summary":"众生药业:控股子公司一类创新药RAY1225注射液用于超重/肥胖患者的II期临床试验完成首例受试者入组。 \n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-21/doc-inaiuyrc0326270.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-02-21/doc-inaiuyrc0326270.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2410069567","title":"创新药物马立巴韦片在中国投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2410069567","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2410069567?lang=zh_cn&edition=full","pubTime":"2024-02-09 10:31","pubTimestamp":1707445860,"startTime":"0","endTime":"0","summary":"北京大学人民医院的黄晓军院士团队、南方医科大学的刘启发主任团队分别在北京和广州开出创新抗巨细胞病毒药物马立巴韦片的首张处方,标志着这一创新药物在中国投入临床使用,为我国难治性CMV感染或疾病的成人移植受者带来治疗新选择。同时,马立巴韦片与常规抗病毒治疗相比,治疗限制性毒性更低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-02-09/doc-inahmafs0343600.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-02-09/doc-inahmafs0343600.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2410774772","title":"东瑞制药(02348.HK)向康方生物(09926.HK)悉售创新药物产品研发合资35%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2410774772","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2410774772?lang=zh_cn&edition=full","pubTime":"2024-02-09 08:33","pubTimestamp":1707438780,"startTime":"0","endTime":"0","summary":"东瑞制药公布,其全资附属东瑞生物向康方生物的全资附属中山康方,悉售东瑞生物于康融东方的35%股权,购买价为2.67亿元人民币(下同)。因此,东瑞生物根据该协议有权收取合共3.9亿元。东瑞制药估计出售事项将确认税前收益净额约2.67亿至2.85亿元,出售所得资源将用于研发项目以及制造及销售活动。康方生物认为,将康融东方创新药物产品全面融入公司旗下肿瘤和非肿瘤产品管线,将有利于该两款产品后续临床开发及商业计划的整体高效运作。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190723164448759_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190723164448759_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325977/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2409479338","title":"远大医药(00512.HK)创新药Ryaltris向药监局递交NDA获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2409479338","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2409479338?lang=zh_cn&edition=full","pubTime":"2024-02-08 17:20","pubTimestamp":1707384000,"startTime":"0","endTime":"0","summary":"远大医药(00512.HK) 公布,集团用于治疗成人和儿童过敏性鼻炎(AR)的全球创新药Ryaltris复方鼻喷剂(GSP 301 NS)近日向中国国家药品监督管理局递交的新药上市申请(NDA)获得受理。GSP 301 NS于2021年10月获药监局批准开展III期临床试验,并于2023年9月成功达到临床终点。该产品于2022年1月获美国食品药品监督管理局(FDA)批准上市,此外,该产品也在澳洲、俄罗斯、韩国、英国和欧盟等多个国家和地区获批上市销售。(sl/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-02-08 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190311162624473_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190311162624473_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325875/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2409203753","title":"康哲药业(00867.HK)两款创新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2409203753","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2409203753?lang=zh_cn&edition=full","pubTime":"2024-02-08 02:58","pubTimestamp":1707332280,"startTime":"0","endTime":"0","summary":"康哲药业(00867.HK) 公布,集团自主研发的创新药CMS-D001片及CMS-D002胶囊近日获中国国家药品监督管理局签发药物临床试验批准通知书。同意开展评价CMS-D001在健康受试者和斑块状银屑病患者安全性、耐受性、药代动力学和疗效的I期临床研究;及评价CMS-D002在健康成年绝经前女性受试者的I期临床研究。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-02-07 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1325616/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"stockEarnings":[{"period":"1week","weight":-0.0411},{"period":"1month","weight":-0.0385},{"period":"3month","weight":-0.1515},{"period":"6month","weight":-0.1716},{"period":"1year","weight":-0.2441},{"period":"ytd","weight":-0.1515}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":-0.0016},{"period":"3month","weight":0.012},{"period":"6month","weight":-0.0321},{"period":"1year","weight":-0.0708},{"period":"ytd","weight":0.012}],"serverTime":1711670430898,"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}